DiscoveryProbe™ FDA-approved Drug Library: Enabling High-Throughput Screening and Drug Repositioning

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (L1021) comprises 2,320 bioactive compounds approved by global regulatory agencies (FDA, EMA, HMA, CFDA, and PMDA), pre-formulated for high-throughput and high-content screening applications [APExBIO]. Each compound is supplied at 10 mM in DMSO, ensuring stability for up to 24 months at -80°C. The library supports drug repositioning and pharmacological target identification by encompassing a diverse array of molecular mechanisms, including receptor agonists/antagonists, enzyme inhibitors, and ion channel modulators. Recent studies have demonstrated the utility of this library in uncovering novel ligand-protein interactions, such as the direct binding of eltrombopag to SDC4 and its impact on MAPK signaling in cancer cells [Am J Cancer Res 2022]. Its modular format enables rapid integration into automated screening workflows, accelerating discovery in cancer, neurodegenerative disease, and mechanistic pathway research [Deep Proteomic Applications].

Biological Rationale

The identification of clinically relevant bioactive compounds is critical for translational research and precision medicine. Traditional drug discovery pipelines are time-consuming and resource-intensive, often yielding low success rates in later-stage clinical trials [Scannell et al., 2016]. By leveraging a pre-validated library of FDA- and internationally approved drugs, researchers can systematically interrogate complex biological networks and rapidly prioritize candidates for repurposing. The DiscoveryProbe™ FDA-approved Drug Library offers a reproducible, regulatory-grade resource for investigating disease models, signaling pathways, and pharmacological mechanisms [HTS Paradigms]. This approach is particularly valuable for diseases with unmet therapeutic needs, such as cancer and neurodegenerative disorders, where repositioning known drugs can bypass many early-stage development hurdles.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ FDA-approved Drug Library contains compounds encompassing a broad range of mechanisms of action. These include:

• Receptor agonists and antagonists: Modulate the activity of G protein-coupled receptors, ion channels, and enzyme-linked receptors, enabling pathway-specific modulation (e.g., doxorubicin, a DNA intercalator and topoisomerase II inhibitor).
• Enzyme inhibitors: Target kinases, phosphatases, proteases, and metabolic enzymes; for example, metformin inhibits mitochondrial respiratory-chain complex I.
• Ion channel modulators: Affect neuronal excitability, cardiac function, and other physiological processes by altering ion flux (e.g., calcium channel blockers).
• Signal pathway regulators: Compounds such as eltrombopag, an FDA-approved thrombopoietin receptor agonist, have been shown to directly bind and activate non-canonical targets such as SDC4, thereby enhancing MAPK signaling and macropinocytosis in cancer cells [Am J Cancer Res 2022].

The molecular diversity of the library supports the interrogation of signaling networks and the identification of context-dependent drug responses, as detailed in this proteomics-driven screening overview, which this article extends by focusing on clinical compound benchmarking and mechanistic clarification.

Evidence & Benchmarks

• DiscoveryProbe™ FDA-approved Drug Library (L1021) includes 2,320 unique, clinically approved compounds, each supplied as a 10 mM DMSO solution, conforming to regulatory standards (APExBIO, product page).
• Eltrombopag, a library component, directly binds SDC4 with a Kd of ~2 μM in vitro, as measured by ligand interaction screening (Cui et al. 2022, Am J Cancer Res 2022).
• Use of the L1021 kit enabled identification of SDC4-dependent MAPK signaling activation and enhanced macropinocytosis in pancreatic cancer cells (Cui et al. 2022, Am J Cancer Res 2022).
• Compounds are stable for 12 months at -20°C and for 24 months at -80°C when dissolved at 10 mM in DMSO (APExBIO, product data).
• The library supports both high-throughput (HTS) and high-content screening (HCS), validated across cancer, neurodegeneration, and infectious disease models (see this HCS-focused resource; this article clarifies mechanistic and regulatory details not covered in the linked piece).
• Shipping options include blue ice or room temperature; evaluation samples are always shipped on blue ice (APExBIO, product page).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is designed to accelerate drug repositioning and pharmacological target identification across diverse research areas:

• Cancer research drug screening: Rapidly identify compounds with anti-tumor activity or those modulating resistance pathways.
• Neurodegenerative disease drug discovery: Screen for neuroprotective agents or modulators of disease-relevant signaling pathways.
• Signal pathway regulation: Map pathway dependencies using clinically validated small molecules.
• Enzyme inhibitor screening: Benchmark or discover new enzyme modulators in disease-relevant models.
• Drug repositioning screening: Repurpose known compounds for novel indications with reduced development timelines.

This article extends the strategic guidance outlined in this thought-leadership overview by providing updated mechanistic benchmarks and regulatory context.

Common Pitfalls or Misconceptions

• Not all mechanisms are equally represented: While the library is comprehensive, rare or emerging target classes may be underrepresented.
• Not suitable for primary de novo discovery: The library is optimized for repurposing and mechanistic studies, not for identifying completely novel chemical scaffolds.
• Matrix and vehicle effects: DMSO at 10 mM stock concentrations may require further dilution to avoid cytotoxicity in sensitive assays.
• Not all compounds are equally soluble in aqueous buffers: End-user optimization of assay conditions is recommended.
• Clinical relevance may vary by model: Positive screening hits require secondary validation in disease-relevant systems.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library can be integrated into automated or manual screening pipelines. Key workflow features include:

• Formats: Available in 96-well microplates, deep well plates, and 2D barcoded screw-top storage tubes for compatibility with robotic platforms.
• Compound concentration: Each compound is provided as a 10 mM solution in DMSO; recommended working concentrations range from 0.1–50 μM, depending on assay design.
• Storage and stability: Stable for 12 months at -20°C or up to 24 months at -80°C. Avoid repeated freeze-thaw cycles.
• Shipping: Standard shipping on blue ice for evaluation samples; room temperature or blue ice for larger sizes upon request.
• Data management: 2D barcoding enables sample tracking and integration with laboratory information management systems (LIMS).

For a more detailed discussion of proteomic screening strategies and data integration, see this resource, which this article updates by providing explicit regulatory and workflow benchmarks.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library, curated and distributed by APExBIO, is a robust toolkit for high-throughput and high-content screening in drug repositioning and mechanistic discovery. Its clinically validated, regulatory-grade compounds provide an unparalleled foundation for translational research. Recent evidence underscores its value in elucidating novel drug-protein interactions, such as eltrombopag's binding to SDC4 and downstream MAPK pathway effects [Am J Cancer Res 2022]. As screening technologies and disease models evolve, the L1021 kit will remain a cornerstone resource for accelerating discovery and advancing precision medicine.